Ann: Expanded collaboration with Siemens Healthineers to US, page-22

well, you need to look a little further, (i know it gets lost in the noise of the gallery) i have only been commenting now and then for the last year or so, but mostly i have been critical on the boy scout ethics in these posts, not to use incentives to boost recruitment of patients. I even commented so, after the recent webinar. So, yes, i have been calling out bad management. But i can not ignore the valuation today, or that we are now heading to phase 2 trials, where recruitment is said to be less the covid anchors of phase 1. So i called out the failing. And i am looking to the future. And the past 200m valuation is just a sniff of the market appetite. Where would it have sailed without the delays that set in.